

703 836 2021

Patent Attorney's Docket No. 001560-390

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of				
Harukazu FUKAMI et al			Group Art Unit: 1624	
Application No.: 09/763,213 Examiner: To be assigned				
Filed:	Febr	uary 20, 2001))	
For:	DEI PH	SCRIPTION QUINAZOLINE RIVATIVES AND ARMACEUTICAL APPLICATIONS EREOF))))	
AMENDMENT/REPLY TRANSMITTAL LETTER				
Assistant Commissioner for Patents Washington, D.C. 20231				
Sir: Enclosed is a Supplemental Preliminary Amendment for the above-identified patent application.				
(
[[] A Terminal Disclaimer and a check for [] \$55.00 (248) [] \$110.00 (148) to cover the requisite Government fee are also enclosed.			
ı	[]	Also enclosed is		
ı		Small entity status is hereby claimed.		
		Applicant(s) request continued examination under 37 C.F.R. § 1.114 and enclose the [] \$355.00 (279) [] \$710.00 (179) fee due under 37 C.F.R. § 1.17(e).		
		[] Applicant(s) previously submitted, on, for which continued examination is requested.		
	[]	Applicant(s) request suspension of action by the Office until at least _, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.		
	[]	A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (146/246) is also enclosed.		
	[X]	No additional claim fee is required.		
	[]	An additional claim fee is required, and	d is calculated as shown below:	

(03/01)